Rosenson, Robert S. http://orcid.org/0000-0002-5599-0633
López, J. Antonio G.
Monsalvo, Maria Laura
Wu, You
Wang, Huei
Marcovina, Santica M.
Funding for this research was provided by:
Amgen
Article History
Accepted: 10 November 2022
First Online: 26 November 2022
Declarations
:
: This study was conducted in accordance with the principles of the Declaration of Helsinki and the International Council for Harmonisation Good Clinical Practice regulations/guidelines. An institutional review board or independent ethics committee reviewed and approved the study protocol and the amendment at each study center.
: Participants provided written informed consent to participate in the study and publish the data before any screening procedures. This report contains no identifying information about individual participants.
: All authors approved the final manuscript and agreed to submit it for consideration for publication.
: RSR reports research support from Amgen, Arrowhead, Lilly, Novartis, NIH, and Regeneron; consulting/advisory roles for Amgen, Arrowhead, CRISPR Therapeutics, Lilly, Novartis, Precision BioSciences, Regeneron, and Ultragenyx; speaking (non-promotional) roles with Amgen, Kowa; stock holdings with MediMergent; and royalties from Wolters Kluwer. RSR and SMM are co-inventors in a patent application on the method described in this article (EFS ID: 43877461, application number 63248837 filed on September 27, 2021). JAGL, MLM, YW, and HW are employees and stockholders of Amgen Inc. SMM reports consulting roles for Roche, Denka, and Novartis and research support from Amgen through Medpace.